Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)

Avatrombopag is the newest thrombopoietin receptor agonist (TPO-RA) approved to treat immune thrombocytopenia (ITP). Real-world evidence regarding effectiveness/safety is limited. The Spanish ITP Group (GEPTI) performed a retrospective study with patients starting avatrombopag for the first time. A...

Descripción completa

Detalles Bibliográficos
Autores: Pascual-Izquierdo, Cristina, Sánchez González, Blanca, Spanish ITP Group (GEPTI) of the Spanish Society of Hematology and Hemotherapy (SEHH)
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/71354
Acceso en línea:http://hdl.handle.net/10230/71354
http://dx.doi.org/10.1002/ajh.27498
Access Level:acceso abierto
Palabra clave:Trombocitopènia
id ES_fb628dee57bcc1bcd9be088cce80da09
oai_identifier_str oai:recercat.cat:10230/71354
network_acronym_str ES
network_name_str España
repository_id_str
spelling Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)Pascual-Izquierdo, CristinaSánchez González, BlancaSpanish ITP Group (GEPTI) of the Spanish Society of Hematology and Hemotherapy (SEHH)TrombocitopèniaAvatrombopag is the newest thrombopoietin receptor agonist (TPO-RA) approved to treat immune thrombocytopenia (ITP). Real-world evidence regarding effectiveness/safety is limited. The Spanish ITP Group (GEPTI) performed a retrospective study with patients starting avatrombopag for the first time. A total of 268 ITP patients were recruited. The median (interquartile range [IQR]) follow-up time was 47.5 (30.4-58.9) weeks. Among the 193 patients with baseline platelet counts <50 × 109/L, 174 (90.1%) of them achieved response (PC ≥50 × 109/L), and 113 (87.6%) of the 129 who persisted on avatrombopag at last visit had platelet levels above such threshold. Results were similar when only those patients switching to avatrombopag due to previous treatment failure were considered (n = 104). Patients reached response in 13 (7-21) days. Among patients with baseline levels ≥50 × 109/L, 73/75 (97.3%) reported response, which was maintained by 53 (94.6%) of the 56 who continued on avatrombopag at the end of the study. Loss-of-response was always <10%. ITP duration did not influence response. Approximately 79% (34/43) of heavily pretreated (≥4 lines) patients with baseline platelet counts <50 × 109/L switching after previous failure achieved PC ≥50 × 109/L. Previous use of eltrombopag and/or romiplostim did not influence response, regardless of whether previous TPO-RA(s) succeeded or failed. Avatrombopag allowed dose-reduction/suspension of corticosteroids in 40/50 (80.0%) patients with baseline platelet counts <50 × 109/L. Overall, 40/268 (14.9%) thrombocytosis and 12/268 (4.5%) thromboembolic events were reported. Our real-world cohort supports the use of avatrombopag to manage ITP, regardless of disease severity and treatment history.Wiley202520252024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/71354http://dx.doi.org/10.1002/ajh.27498http://hdl.handle.net/10230/71354reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésAm J Hematol. 2024 Dec;99(12):2328-39© 2024 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/713542026-05-29T05:05:01Z
dc.title.none.fl_str_mv Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)
title Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)
spellingShingle Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)
Pascual-Izquierdo, Cristina
Trombocitopènia
title_short Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)
title_full Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)
title_fullStr Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)
title_full_unstemmed Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)
title_sort Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)
dc.creator.none.fl_str_mv Pascual-Izquierdo, Cristina
Sánchez González, Blanca
Spanish ITP Group (GEPTI) of the Spanish Society of Hematology and Hemotherapy (SEHH)
author Pascual-Izquierdo, Cristina
author_facet Pascual-Izquierdo, Cristina
Sánchez González, Blanca
Spanish ITP Group (GEPTI) of the Spanish Society of Hematology and Hemotherapy (SEHH)
author_role author
author2 Sánchez González, Blanca
Spanish ITP Group (GEPTI) of the Spanish Society of Hematology and Hemotherapy (SEHH)
author2_role author
author
dc.subject.none.fl_str_mv Trombocitopènia
topic Trombocitopènia
description Avatrombopag is the newest thrombopoietin receptor agonist (TPO-RA) approved to treat immune thrombocytopenia (ITP). Real-world evidence regarding effectiveness/safety is limited. The Spanish ITP Group (GEPTI) performed a retrospective study with patients starting avatrombopag for the first time. A total of 268 ITP patients were recruited. The median (interquartile range [IQR]) follow-up time was 47.5 (30.4-58.9) weeks. Among the 193 patients with baseline platelet counts <50 × 109/L, 174 (90.1%) of them achieved response (PC ≥50 × 109/L), and 113 (87.6%) of the 129 who persisted on avatrombopag at last visit had platelet levels above such threshold. Results were similar when only those patients switching to avatrombopag due to previous treatment failure were considered (n = 104). Patients reached response in 13 (7-21) days. Among patients with baseline levels ≥50 × 109/L, 73/75 (97.3%) reported response, which was maintained by 53 (94.6%) of the 56 who continued on avatrombopag at the end of the study. Loss-of-response was always <10%. ITP duration did not influence response. Approximately 79% (34/43) of heavily pretreated (≥4 lines) patients with baseline platelet counts <50 × 109/L switching after previous failure achieved PC ≥50 × 109/L. Previous use of eltrombopag and/or romiplostim did not influence response, regardless of whether previous TPO-RA(s) succeeded or failed. Avatrombopag allowed dose-reduction/suspension of corticosteroids in 40/50 (80.0%) patients with baseline platelet counts <50 × 109/L. Overall, 40/268 (14.9%) thrombocytosis and 12/268 (4.5%) thromboembolic events were reported. Our real-world cohort supports the use of avatrombopag to manage ITP, regardless of disease severity and treatment history.
publishDate 2024
dc.date.none.fl_str_mv 2024
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/71354
http://dx.doi.org/10.1002/ajh.27498
http://hdl.handle.net/10230/71354
url http://hdl.handle.net/10230/71354
http://dx.doi.org/10.1002/ajh.27498
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Am J Hematol. 2024 Dec;99(12):2328-39
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425324450643968
score 15,812429

Similares en LA Referencia